Opthea Options Exercise Generates Proceeds of A$13.3m
Filed with ASX · · 3 pages · English
Earlier from Opthea
- Opthea confirms final patient enrolment in Ph2b wAMD trial
- Opthea Phase 2b wAMD trial fully recruited ahead of schedule
- Opthea Receives A$12m R&D Tax Incentive
- Opthea CEO Presentation of Trial Updates at OIS@AAO 2018
- Opthea Doses First Patients in Australia for Phase 2a in DME
Later from Opthea
- Opthea Granted Japanese Patent Covering OPT-302
- Opthea Ph2b Trial Advances With 2nd Positive Safety Review
- S&P DJI Announces March 2019 Quarterly Rebalance
- Opthea Completes Final Patient Visit in Phase 2b wAMD Trial
- Opthea Provides Timing Update on OPT-302 Clinical Trials
Follow Opthea into a list and get an email when it puts out news.
Follow Opthea